Modern Vaccines Adjuvants Formulation

18-20 May 2016, Eigtveds Pakhus, Copenhagen, Denmark

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

In Association with the Statens Serum Institut, Copenhagen, Denmark

Join the conversation on Twitter – #MVAF2016

The increasing need for new and improved vaccines and the growing level of sophistication of their associated adjuvantation and delivery systems has major implications for the design, formulation, delivery, manufacturing and quality assessment of modern vaccines and immune interventions in general. MVAF 2016 will be the fifth meeting in this successful series and again will offer an international forum for the discussion of all aspects of vaccine and adjuvant formulation and will focus on:

Innovation in vaccine design and adjuvantation/delivery technologies
Challenges to manufacturing and the administration of modern vaccines
Compliance with quality standards and regulatory requirements

MVAF 2016 will then assess the impact of all of the above on the future development/design of vaccines and adjuvants.

MVAF 2016 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups. Contributions to both the oral and poster programs are encouraged. Potential contributors attention is drawn to the Call For Abstracts on the reverse of this brochure.

Scientific Advisory Panel

Conference Chairmen: Peter Andersen (SSI, Copenhagen, Denmark) and Dennis Christensen (SSI, Copenhagen, Denmark)

Nathalie Garcon (BIOASTER Research Technology Institute, Lyon, France)
Adriana Baz Morelli (CSL Ltd, Melbourne, Australia)
Jean Haensler (Sanofi Pasteur, Lyon, France)
Manmohan Singh (Takeda Vaccines Inc., Morrisville, North Carolina, USA)
Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)
Niranjan Sardesai (Inovio Inc., Plymouth Meeting, Pennsylvania, USA)
Heather Davis (Seqirus, Maidenhead, Berkshire, UK)
Chris Fox (IDRI, Seattle, Washington, USA)
Nicolas Collin (University of Lausanne, Lausanne, Switzerland)
Stephaen Ascarateil (SEPPIC, Paris, France)
Quentin Sattentau (University of Oxford, Oxford, UK)
Ken Ishii (University of Osaka, Osaka, Japan)
Erik Lindblad (Brenntag Biosector, Frederikssund, Denmark)
Gideon Kersten (Intravacc, Bilthoven, The Netherlands)

Conference Scope

The following list of topics is not exhaustive but reflects the variety of subjects that this area of vaccine/adjuvant technology and development encompasses:

Innovative Vaccine Concepts and Designs
Molecular Approaches to Vaccine Design
Vaccine Immunology/Immunogenicity Studies
Vaccine Design & Formulation
Modelling Methods
Vaccine/Adjuvant Delivery Issues & Systems
Vaccine/Adjuvant Diversity – Live or Inactivated Virus/Recombinant Protein
Polysaccharide or Peptide (free versus conjugated)
Viral Vectors/DNA Vectors
VLPs & Nanoparticulate Vaccines
Administration Devices/Methods (oral/nasal/transcutaneous/needle-free)

Process & Manufacturing
Protein Stabilization/Virus Stablization/Vaccine Stabilization
Vaccine Preservation Issues – New/Novel Vaccine Preservatives
Vaccine Stability Monitoring Methods

Characterization and quality assessment in compliance with regulatory guidelines
Vaccine/Adjuvant Quality, Purity & Potency/Efficacy & Safety
Safety Evaluation Considerations
Assay Development Aspects
Toxicology Studies
Regulatory Guidelines – National/International for Adjuvanted Vaccines

 

MVAF 2016 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2016 Sponsors

  • Mucosis
  • NanoTemper Technologies
  • CureVac
  • hVIVO
  • Aldevron
  • Pfizer
  • Inovio
  • Brenntag
  • IntraVacc
  • Bioaster
  • NatureGeneTherapy.com
  • Vaxart
  • DNAvaccine.com
  • IDRI
  • Seppic
  • EVI
  • Sanofi Pasteur

MVAF 2016 Downloads

MVAF 2016 Leaflet

MVAF 2016 Mailing List

Name
E-mail Address
What is 3+2-1?